Open access · CC-BY
via OpenAlex
Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study)
Thomas Hugh Jones, Stefan Arver, Hermann M. Behre, Jacques Buvat, ERIC J. H. MEULEMAN, Ignacio Moncada, Antonio Martín Morales, Maurizio Volterrani, Ann Yellowlees, Julian D. Howell, Kevin Stephen Channer, TIMES2 Investigators
Diabetes Care · 2011 · ▲ 552 citations
Abstract
OBJECTIVE: This study evaluated the effects of testosterone replacement therapy (TRT) on insulin resistance, cardiovascular risk factors, and symptoms in hypogonadal men with type 2 diabetes and/or metabolic syndrome (MetS). RESEARCH DESIGN AND METHODS: The efficacy, safety, and tolerability of a novel transdermal 2% testosterone gel was evaluated over 12 months in 220 hypogonadal men with type 2 diabetes and/or MetS in a multicenter, prospective, randomized, double-blind, placebo-controlled study. The primary outcome was mean change from baseline in homeostasis model assessment of insulin resistance (HOMA-IR). Secondary outcomes were measures of body composition, glycemic control, lipids, and sexual function. Efficacy results focused primarily on months 0-6 (phase 1; no changes in medication allowed). Medication changes were allowed in phase 2 (months 6-12). RESULTS: TRT reduced HOMA-IR in the overall population by 15.2% at 6 months (P = 0.018) and 16.4% at 12 months (P = 0.006). In type 2 diabetic patients, glycemic control was significantly better in the TRT group than the placebo group at month 9 (HbA(1c): treatment difference, -0.446%; P = 0.035). Improvements in total and LDL cholesterol, lipoprotein a (Lpa), body composition, libido, and sexual function occurred in selected patient groups. There were no significant differences between groups in the frequencies of adverse events (AEs) or serious AEs. The majority of AEs (>95%) were mild or moderate. CONCLUSIONS: Over a 6-month period, transdermal TRT was associated with beneficial effects on insulin resistance, total and LDL-cholesterol, Lpa, and sexual health in hypogonadal men with type 2 diabetes and/or MetS.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.2337/dc10-1233
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
Jones, T.H., Arver, S., Behre, H.M., Buvat, J., MEULEMAN, E.J.H., Moncada, I., Morales, A.M., Volterrani, M., Yellowlees, A., Howell, J.D., Channer, K.S., & Investigators, T. (2011). Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study). <em>Diabetes Care</em>. https://doi.org/10.2337/dc10-1233
Vancouver
Jones TH, Arver S, Behre HM, Buvat J, MEULEMAN EJH, Moncada I, et al. Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study). Diabetes Care. 2011. doi:10.2337/dc10-1233.
BibTeX
@article{thomas2011Testos,
title = {Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study)},
author = {Thomas Hugh Jones and Stefan Arver and Hermann M. Behre and Jacques Buvat and ERIC J. H. MEULEMAN and Ignacio Moncada and Antonio Martín Morales and Maurizio Volterrani and Ann Yellowlees and Julian D. Howell and Kevin Stephen Channer and TIMES2 Investigators},
journal = {Diabetes Care},
year = {2011},
doi = {10.2337/dc10-1233},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
International Journal of Endocrinology 2020
Open access · CC-BY
Metabolic Effects of Testosterone Replacement Therapy in Patients with Type 2 Diabetes Mellitus or Metabolic Syndrome: A Meta-Analysis
DOAJ (DOAJ: Directory of Open Access Journals) 2016
Preprint · CC-BY
A NEW MARKER OF METABOLIC DISORDERS IN MEN WITH TYPE 2 DIABETES
The Journal of Sexual Medicine 2013
Citation only
Testosterone Replacement Therapy Improves Metabolic Parameters in Hypogonadal Men with Type 2 Diabetes but Not in Men with Coexisting Depression: The BLAST Study
Diabetes Care 2010
Open access · CC-BY
Impact of BMI and the Metabolic Syndrome on the Risk of Diabetes in Middle-Aged Men
The Aging Male 2003
Open access · OA
Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency
Diabetes Care 2005
Open access · OA